NEJM Publishes Phase 1/2 Results for Denali Therapeutics’ Brain‑Penetrant Hunter Syndrome Therapy

A newly published Phase 1/2 study in The New England Journal of Medicine, and reported on by the Manila Times, highlights promising early results for tividenofusp alfa (DNL310), Denali Therapeutics’ investigational…

Continue Reading NEJM Publishes Phase 1/2 Results for Denali Therapeutics’ Brain‑Penetrant Hunter Syndrome Therapy

GLP-1 Therapies Emerge as Key Tools in CKD Prevention—But Long-Term Success Hinges on Patient Engagement

As reported on Healio, glucagon-like peptide-1 (GLP-1)–based therapies are rapidly reshaping the landscape of diabetes and chronic kidney disease (CKD) management. Originally developed for glycemic control, these agents now play…

Continue Reading GLP-1 Therapies Emerge as Key Tools in CKD Prevention—But Long-Term Success Hinges on Patient Engagement